AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies (TREM)
Sponsor: AstraZeneca
This PHASE2 trial investigates Lung Cancer and Targeted Therapy and is currently ongoing. AstraZeneca leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Apr 2025 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Apr 2022 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Oslo University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .